CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

Aristos

Aristos is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Womens International Pharmacy

It is the goal of Women's International Pharmacy, Inc. to provide excellent service and quality compounded prescriptions to our customers. At Women's International Pharmacy, Inc., we are dedicated to providing custom compounded doses of bioidentical

UPM Pharmaceuticals

UPM Pharmaceuticals is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GreenwichBiosciences

Greenwich Biosciences is the leader in researching cannabinoid medicines for rare epilepsies like Dravet Syndrome, LGS, TSC, and others.

Ohr Pharmaceutical

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.